Promising compound selected as drug candidate for tuberculosis

September 17, 2012, University of Auckland

(Medical Xpress)—A New Zealand-designed compound that shows promise against treatment-resistance tuberculosis (TB) has been selected as a drug candidate by international non-profit drug developer the Global Alliance for TB Drug Development (TB Alliance).

The compound, TBA-354, was designed by scientists at the Auckland Cancer Society Research Centre (ACSRC) and Maurice Wilkins Centre for Molecular Biodiscovery in partnership with the TB Alliance and the University of Illinois at Chicago.

TBA-354 has been more potent in preclinical studies than another compound in its class, PA-824, which has already shown promise in clinical trials. This is the first new class of drugs to be developed for TB in nearly 50 years, and the first designed to work against the persistent form of the disease.

Clinical results reported earlier this year suggest that PA-824, in combination with an existing TB drug, could treat some drug resistant forms of TB in just four months in contrast to the 18-24 months required for current regimens. TBA-354, the follow-on compound, may prove to be even more effective.

"TBA-354 is an improved, second-generation version of PA-824," says Professor Bill Denny, Co-Director of the ACSRC and a Maurice Wilkins Centre principal investigator. "It is much more potent than PA-824, longer lasting, and has greater activity against of the disease. Recent trials by the TB Alliance show that PA-824 can shorten the treatment period for TB and it's encouraging that in TBA-354 we have a compound that is clearly superior to PA-824."

"This has been an excellent and productive collaboration, across groups with different skills, where we have learned much from each other that we can apply in future," says Associate Professor Brian Palmer of the ACSRC and Maurice Wilkins Centre, who led the project's chemistry team of Drs Adrian Blaser, Iveta Kmentova, Hamish Sutherland and Andrew Thompson.

The TB Alliance expects to complete of TBA-354 by early 2013 and will then seek permission from the US Food and Drug Administration to begin trials in humans.

Professor Denny says that when PA-824 was discovered it clearly showed promise but had limitations and little was known about the nitroimidazole class to which it belongs. The New Zealand scientists discovered how to optimise each part of the drug, designing and synthesising nearly a thousand "second generation" molecules and sending the best of them to colleagues at the University of Illinois at Chicago for testing. In the process they also developed a new method for synthesising the drugs, which will simplify and reduce the cost of production.

TBA-354 emerged as the most promising candidate, with the greatest potency against TB. At the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco this week the TB Alliance announced that TBA-354 had been selected for further development.

"New Zealand has an outstanding reputation in drug discovery and it's exciting to see the ACSRC's expertise in cancer drug development being used in the fight against one of the most devastating infectious diseases in the world," says Professor Rod Dunbar, Director of the Maurice Wilkins Centre. "Skills honed over decades at the ACSRC with a focus on cancer have been very elegantly applied to a completely different kind of disease, showing how broadly our clever scientists can apply their expertise."

TB is second only to HIV/AIDS as the greatest infectious killer worldwide, and while with most cases and deaths occur in low and middle-income countries, it is a major health concern in the Asia-Pacific region. Treatment regimens are complex, lengthy and challenging to follow and the disease is developing resistance to current antibiotics, especially in its persistent form. If a potent new like TBA-354 proves more effective against TB than current treatments it has the potential to reduce the duration, cost and side-effects of treatment.

Explore further: Trial for new drug-resistant TB treatment to begin

Related Stories

Trial for new drug-resistant TB treatment to begin

March 19, 2012
A global health alliance Monday unveiled plans for the first clinical tests of a new treatment regimen for tuberculosis, including for patients with resistance to existing multidrug programs.

S.Africa conducts trials for shorter TB treatment

March 30, 2012
South African researchers said Friday they were conducting medical trials to shorten the duration of tuberculosis treatment to make it easier for patients to complete the full regimen.

Trial signals major milestone in hunt for new TB drugs

July 23, 2012
A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two ...

Researchers validate preclinical effectiveness of TB drug target

November 29, 2011
In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten ...

Scientists: Novel TB drug combo passes first test

July 23, 2012
Scientists are hot on the trail of a new tuberculosis treatment that a small study suggests might one day offer an alternative to battle this deadly lung disease, even if it is resistant to today's two main drugs.

Recommended for you

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

Fresh approach to tuberculosis vaccine offers better protection

January 17, 2018
A unique platform that resulted in a promising HIV vaccine has also led to a new, highly effective vaccine against tuberculosis that is moving toward testing in humans.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.